real-world analysis of the most study: factors impacting progression to mf in patients with et
Published 6 months ago • 127 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
0:46
simplify studies: analysis of the meaningful symptomatic change in patients with myelofibrosis
-
7:09
the role of real-world evidence in the evaluation of new drugs
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
1:20
a real-world study evaluating combined modality therapy for early-stage hodgkin lymphoma
-
2:10
drd versus vrd in patients with mm: a real-world retrospective analysis
-
1:17
retrospective real-world study evaluating compassionate use of ponatinib in r/r ph-like all
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:09
real-world data analysis of ruxolitinib in myelofibrosis
-
3:02
durability of response & biomarker changes in the manifest study
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
2:41
an overview of the latest advances in hematology
-
6:31
the importance of patient perspectives and real-world data
-
4:09
real-world safety and efficacy of liso-cel in r/r large b-cell lymphoma
-
1:34
are thrombotic risk and progression in et predictable?